Uterine Sarcoma

Uterine sarcomas (cancers arising from bone or soft tissue) are a very rare form of uterine cancer that develop in muscles of the uterus. The uterus is a pear-shaped organ of the female reproductive system where fetal growth and development occur.

The uterus is made up of three layers: the endometrium, myometrium, and perimetrium (mucus layer protecting the uterus). The endometrium is the inner lining of the uterus, and is the layer that grows thick and sheds when fertilisation does not occur. This occurs monthly in a process known as menstruation. Cancers that develop in the endometrium are much more common, and are called endometrial cancers. For more information on endometrial cancers, please visit the Rare Cancers Australia Endometrial (uterine) cancer page.

The myometrium is the muscular, middle layer that makes up most of the uterus. It is responsible for holding the structure of the uterus, expanding to enable fetal growth, and inducing uterine contractions during childbirth. Cancers of the myometrium are considered to be very rare.

Uterine sarcomas are most common in post-menopausal women who are over 60 years old, however it can affect anyone with a uterus – including pre-menopausal women, teenagers, transgender men, non-binary individuals, and intersex people – at any age.

Types of Uterine Sarcomas

There are three different types of uterine sarcomas, which are categorised by the types of cells the cancer originates from.

Leiomyosarcomas

Leiomyosarcomas are the most common form of uterine sarcoma, and develop from the smooth muscle cells of the myometrium. They are often aggressive, often metastasise, and generally have a high recurrence rate. However, leiomyosarcomas can have a good prognosis when caught early. For more information on leiomyosarcomas, please refer to the Rare Cancers Australia Leiomyosarcoma page.

Endometrial Stromal Sarcoma

Endometrial stromal sarcomas are rare malignancies that develop in the connective tissue (or stroma) of the endometrium. These tumours are most often found in pre-menopausal women between the ages of 40 -50. Endometrial stromal tumours are usually non-aggressive, are relatively slow growing, and may have a good prognosis when caught early.

Undifferentiated Uterine Sarcoma

Undifferentiated uterine sarcomas are rare malignancies that can start in either the endometrium or the myometrium. This type of cancer is often considered to be aggressive, often metastasise and may have high recurrence rates. Unfortunately, undifferentiated uterine sarcomas may not have as good of a prognosis as other uterine sarcomas.

Rare types of Uterine Sarcoma

These types of cancers are considered to be very rare:

  • Uterine carcinosarcoma (a mixed uterine cancer with features of endometrial cancers and uterine sarcomas).
  • Uterine adenosarcoma (a mixed uterine cancer with features of benign tumours (adenomas) and uterine sarcomas).

Treatment

If a uterine sarcoma is detected, it will be staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you.

FIGO Staging System

Gynaecological cancers, such as uterine sarcomas, can be staged using the Federation of Gynaecology and Obstetrics (FIGO) system from stage I to IV:

  • Stage I: cancer cells are confined to the uterus only. This stage is also known as early-stage cancer.
  • Stage II: cancer cells have grown deeper into nearby organs in the pelvis, such as the ovaries, fallopian tubes, bladder and/or bowel. This is also known as localised cancer.
  • Stage III: the cancer has become larger and has spread beyond the pelvis into the lining of the abdomen (peritoneum). Lymph nodes are also often affected. This is also known as advanced or metastatic cancer.
  • Stage IV: the cancer has spread to more distant organs, such as the lungs or the liver. This is also known as advanced or metastatic cancer.

TNM Staging System

The TNM system can also be used to classify a uterine sarcoma. The TNM system is comprised of:

  • T (tumour) indicates the size and depth of the tumour.
  • N (node) indicates whether the cancer has spread to nearby lymph nodes.
  • M (metastasis) indicates whether the cancer has spread to other parts of the body.

This system can also be used in combination with a numerical value, from stage 0-IV:

  • Stage 0: this stage describes cancer cells in the place of origin (or ‘in situ’) that have not spread to nearby tissue.
  • Stage I: cancer cells have begun to spread to nearby tissue. It is not deeply embedded into nearby tissue and had not spread to lymph nodes. This stage is also known as early-stage cancer.
  • Stage II: cancer cells have grown deeper into nearby tissue. Lymph nodes may or may not be affected. This is also known as localised cancer.
  • Stage III: the cancer has become larger and has grown deeper into nearby tissue. Lymph nodes are generally affected at this stage. This is also known as localised cancer.
  • Stage IV: the cancer has spread to other tissues and organs in the body. This is also known as advanced or metastatic cancer.

Cancers can also be graded based on the rate of growth and how likely they are to spread:

  • Grade I: cancer cells present as slightly abnormal and are usually slow growing. This is also known as a low-grade tumour.
  • Grade II: cancer cells present as abnormal and grow faster than grade-I tumours. This is also known as an intermediate-grade tumour.
  • Grade III: cancer cells present as very abnormal and grow quickly. This is also known as a high-grade tumour.

Once your tumour has been staged and graded, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. They will then discuss the most appropriate treatment option for you.

Treatment Options

Treatment is dependent on several factors, including location, stage of disease and overall health.

Treatment options for uterine sarcomas may include:

  • Surgery, potentially including:
    • Hysterectomy.
    • Bilateral salpingo-oophorectomy.
    • Unilateral salpingo-oophorectomy.
    • Lymphadenectomy.
    • Trachelectomy.
  • Chemotherapy.
  • Radiation therapy.
  • Hormone therapy.
  • Clinical trials.
  • Palliative care.

Uterine Sarcoma Treatment and Fertility

Treatment for uterine sarcoma may make it difficult to become pregnant. If fertility is important to you, discuss your options with your doctor and a fertility specialist prior to the commencement of treatment.

Risk factors

While the cause of uterine sarcomas remains unknown, the following factors may increase the risk of developing the disease:

  • Having had radiation for a cancer in the pelvic area.
  • Having used the Tamoxifen hormone therapy drug for breast cancer over a long period of time (5+ years).
  • Having a genetic mutation in the retinoblastoma tumour suppressor gene (RB1).

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

Symptoms of a uterine sarcoma may include:

  • Unusual bleeding in-between periods.
  • Bleeding after menopause.
  • A mass or lump in the vagina.
  • Abdominal pain.
  • Pelvic pain.
  • Feeling of abdominal fullness.
  • Polyuria.
  • Abnormal vaginal discharge.
  • Unexplained weight loss.

Not everyone with the symptoms above will have cancer but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a uterine sarcoma, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Pelvic examination.
  • Imaging tests, potentially including:
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • Transvaginal ultrasound.
    • Pelvic ultrasound.
  • Blood tests.
  • Hysteroscopy.
  • Biopsy, potentially including:
    • Endometrial (pipelle) biopsy.
    • Dilation and curettage (D&C).

References

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.